Table I.
Characteristics of the patients
| Resequencing analysis (n = 98; 105 samples) | miR-16-1 analysis; Sanger sequencing (n = 193) | miR-29b-2/29c analysis; Sanger sequencing (n = 213) | |
|---|---|---|---|
| Rai stage (at the time of sample collection) | |||
| 0–2 (low/intermediate stage) | 72/98 (74%) | 135/193 (70%) | 153/213 (72%) |
| 3–4 (advanced stage) | 17/98 (17%) | 46/193 (24%) | 48/213 (22%) |
| NA | 9/98 (9%) | 12/193 (6%) | 12/213 (6%) |
| Sex ratio (M:F) | 60:38 | 118:75 | 131:82 |
| Age at diagnosis - years (median) | 62.3 | 60 | 60 |
| IGHV mutation status | |||
| Unmut | 81/98 (83%) | 122/193 (63%) | 135/213 (63%) |
| Mut | 16/98 (16%) | 67/193 (35%) | 74/213 (35%) |
| NA | 1/98 (1%) | 4/193 (2%) | 4/213 (2%) |
| Cytogenetic aberrations (I-FISH) according to hierarchical cytogenetics (8) (at the time of sample collection) | |||
| Del17p | 23/105 (22%) | 38/193 (20%) | 40/213 (19%) |
| Del11q | 47/105 (45%) | 21/193 (11%) | 31/213 (15%) |
| Trisomy 12 | 3/105 (3%) | 29/193 (15%) | 30/213 (14%) |
| Del13q | 20/105 (19%) | 65/193 (34%) | 71/213 (33%) |
| Normal karyotype | 12/105 (11%) | 40/193 (21%) | 41/213 (19%) |
| TP53 mutation status (60) (at the time of sample collection) | |||
| del17p + mutTP53 | 19/105 (18%) | 32/193 (17%) | 34/213 (16%) |
| Sole mutTP53 | 29/105 (28%) | 8/193 (4%) | 9/213 (4%) |
| wtTP53 | 57/105 (54%) | 153/193 (79%) | 170/213 (80%) |
NA, not available.